FUJIFILM Diosynth Biotechnologies U.S.A. officially opened the facility earlier this morning at a ribbon cutting ceremony attended by local government and biotech community members.
The Contract Development and Manufacturing Organization (CDMO) focuses on developing and manufacturing recombinant biopharmaceuticals, including proteins, vaccines, and monoclonal antibodies.
“The construction and completion of this building reflects the continued commitment of our organization to provide our clients with the infrastructure to efficiently and innovatively bring their products to the clinic and beyond for the benefit of their patients,” said Steve Bagshaw, CEO, FUJIFILM Diosynth Biotechnologies.
The building houses the company’s Process and Analytical Research and Development, Process Sciences and Stability groups, which, according to the company, will focus on delivery process invention, design and development, and process and product characterization for its clients.
The groups will also continue to develop the company’s biomanufacturing systems and approaches.
“The design of the facility reflects our core philosophy of cross-functional collaboration to Research and Process Development which is a key differentiator of our company,” said Martin Meeson, President, FUJIFILM Diosynth Biotechnologies U.S.A., Inc.